139 related articles for article (PubMed ID: 16223608)
41. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool.
Hashida H; Miyamoto M; Cho Y; Hida Y; Kato K; Kurokawa T; Okushiba S; Kondo S; Dosaka-Akita H; Katoh H
Br J Cancer; 2004 Mar; 90(6):1252-8. PubMed ID: 15026809
[TBL] [Abstract][Full Text] [Related]
42. HIV-1 TAT-mediated protein transduction of human HPRT into deficient cells.
Cattelan P; Dolcetta D; Hladnik U; Fortunati E
Biochem Biophys Res Commun; 2013 Nov; 441(1):114-9. PubMed ID: 24129187
[TBL] [Abstract][Full Text] [Related]
43. Effects of the HIV-1 viral protein TAT on central neurotransmission: role of group I metabotropic glutamate receptors.
Neri E; Musante V; Pittaluga A
Int Rev Neurobiol; 2007; 82():339-56. PubMed ID: 17678970
[TBL] [Abstract][Full Text] [Related]
44. TAT-mediated protein transduction: delivering biologically active proteins to the heart.
Gustafsson AB; Gottlieb RA; Granville DJ
Methods Mol Med; 2005; 112():81-90. PubMed ID: 16010012
[TBL] [Abstract][Full Text] [Related]
45. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.
Reczek D; Schwake M; Schröder J; Hughes H; Blanz J; Jin X; Brondyk W; Van Patten S; Edmunds T; Saftig P
Cell; 2007 Nov; 131(4):770-83. PubMed ID: 18022370
[TBL] [Abstract][Full Text] [Related]
46. Topical transduction of superoxide dismutase mediated by HIV-1 Tat protein transduction domain ameliorates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice.
Song HY; Lee JA; Ju SM; Yoo KY; Won MH; Kwon HJ; Eum WS; Jang SH; Choi SY; Park J
Biochem Pharmacol; 2008 Mar; 75(6):1348-57. PubMed ID: 18164693
[TBL] [Abstract][Full Text] [Related]
47. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Kim D; Jeon C; Kim JH; Kim MS; Yoon CH; Choi IS; Kim SH; Bae YS
Exp Cell Res; 2006 May; 312(8):1277-88. PubMed ID: 16466653
[TBL] [Abstract][Full Text] [Related]
48. HIV-1-Tat potentiates CXCL12/stromal cell-derived factor 1-induced downregulation of membrane CXCR4 in T lymphocytes through protein kinase C zeta.
Hidalgo-Estévez AM; Punzón C; Sanchez-Duffhues G; Muñoz E; Fresno M
Mol Immunol; 2008 Nov; 46(1):106-15. PubMed ID: 18760839
[TBL] [Abstract][Full Text] [Related]
49. The expression of CD154 by Kaposi's sarcoma cells mediates the anti-apoptotic and migratory effects of HIV-1-TAT protein.
Cantaluppi V; Deregibus MC; Biancone L; Deambrosis I; Bussolati B; Albini A; Camussi G
Int J Immunopathol Pharmacol; 2006; 19(1):81-96. PubMed ID: 16569346
[TBL] [Abstract][Full Text] [Related]
50. Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery.
Sloots A; Wels WS
FEBS J; 2005 Aug; 272(16):4221-36. PubMed ID: 16098203
[TBL] [Abstract][Full Text] [Related]
51. A TAT-modified fusion protein efficiently penetrates mouse hypoglossal nuclei from transduced ependyma.
Alisky JM; Xia H; Davidson BL
Neurosci Lett; 2006 Jun; 401(1-2):40-3. PubMed ID: 16650576
[TBL] [Abstract][Full Text] [Related]
52. Purification of TAT-C3 exoenzyme.
Sahai E; Olson MF
Methods Enzymol; 2006; 406():128-40. PubMed ID: 16472655
[TBL] [Abstract][Full Text] [Related]
53. Tat-mediated protein delivery in living Caenorhabditis elegans.
Delom F; Fessart D; Caruso ME; Chevet E
Biochem Biophys Res Commun; 2007 Jan; 352(3):587-91. PubMed ID: 17141180
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy.
Doublier S; Zennaro C; Spatola T; Lupia E; Bottelli A; Deregibus MC; Carraro M; Conaldi PG; Camussi G
AIDS; 2007 Feb; 21(4):423-32. PubMed ID: 17301560
[TBL] [Abstract][Full Text] [Related]
55. Ciliary neurotrophic factor infused intracerebroventricularly shows reduced catabolic effects when linked to the TAT protein transduction domain.
Vieira AS; Rezende AC; Grigoletto J; Rogério F; Velloso LA; Skaper SD; Negro A; Langone F
J Neurochem; 2009 Sep; 110(5):1557-66. PubMed ID: 19573019
[TBL] [Abstract][Full Text] [Related]
56. Recombinant human immunodeficiency virus type 1 (HIV-1) Tat protein inhibits phagolysosomal fusion in human peripheral blood monocytes.
Pittis MG; Prada F; Sternik G; Sen L
Viral Immunol; 1996; 9(3):169-74. PubMed ID: 8890475
[TBL] [Abstract][Full Text] [Related]
57. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors.
Al-Taei S; Penning NA; Simpson JC; Futaki S; Takeuchi T; Nakase I; Jones AT
Bioconjug Chem; 2006; 17(1):90-100. PubMed ID: 16417256
[TBL] [Abstract][Full Text] [Related]
58. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
59. Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.
Ma X; Zheng W; Wei D; Ma Y; Wang T; Wang J; Liu Q; Yang S
Protein Expr Purif; 2006 May; 47(1):36-44. PubMed ID: 16260148
[TBL] [Abstract][Full Text] [Related]
60. Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef.
Giese SI; Woerz I; Homann S; Tibroni N; Geyer M; Fackler OT
Virology; 2006 Nov; 355(2):175-91. PubMed ID: 16916529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
